Skip to main content

picking a treatment center when you're stage III - what actually matters

Family · · 1,779 views
So Joe got his diagnosis in September and by the time we landed at Moffitt in Tampa for his first consult I was already exhausted from googling everything. Stage III pleural meso and I'm thinking okay we need the best surgeon, the best oncologist, the best everything because this is serious.

But here's what I actually learned that mattered. We visited three centers before deciding, and it wasn't just about who has the fanciest facility. It was about whether they actually do multimodal treatment as their standard, not as some special thing they do sometimes. Moffitt does pleurectomy plus chemo plus sometimes immunotherapy all as one protocol. That consistency matters because they know what works together.

Second thing is asking straight up how many cases like yours they do per year. Joe's surgeon had done over 200 pleurectomies. Not 50, not 100. Two hundred. That's a different level of experience and I could tell in how he talked about the complications, the recovery timing, all of it. He wasn't guessing.

And honestly the team chemistry thing is real. I taught high school for 32 years and I can spot when people actually work together versus just work at the same place. When we met with Joe's surgeon, oncologist, and the immunotherapy specialist all together, they were finishing each other's thoughts about his scans. They'd already been talking about his case. That's the place.

Don't get hung up on distance if there's a real difference in quality. We're in Tampa and Moffitt is here so that worked out, but I would have driven to Houston or Boston if that's where the right team was. You're not gonna want to do this twice.

Also ask about their follow-up protocols after treatment. Where does Joe go for scans? Who reads them? Is it the same team or some random radiologist? We got a whole plan for that which made me feel less terrified about what comes after.

Has anyone else been through picking a center? What made you choose where you went?

8 Replies

Medical Expert Response
What you figured out is exactly right, and I want to add some data behind it because I think it helps when you're second-guessing a decision this big.

Volume matters more than almost anything else for mesothelioma specifically. The MARS 2 trial published in 2022 looked at outcomes for pleurectomy/decortication and one of the consistent findings across the literature is that surgeon volume and institutional experience are independent predictors of surgical mortality. 200 cases is genuinely meaningful. A surgeon doing 5 a year is operating from a fundamentally different knowledge base, and that shows up in how they handle complications, not just in the OR but in what they expect and catch afterward.

The multidisciplinary team piece you described, where they were already talking about Joe's case before you walked in, that's called a tumor board and honestly not every center that claims to have one actually uses it the way Moffitt does. I've seen places where the "team" is really just one person who occasionally emails a colleague. What you witnessed is the real version.

One thing families sometimes overlook is asking specifically about clinical trial access. Stage III pleural meso at a high-volume center means Joe may be eligible for combinations that aren't standard yet, and that can matter. The CheckMate 743 data on nivolumab plus ipilimumab changed first-line thinking pretty significantly for certain histologies, and trials building on that are running at places like Moffitt right now.

Talk to Joe's oncologist about what trials he might qualify for, even if treatment has started. Windows open and close on these things.
4 found this helpful
Family
Oh this is such a good post and honestly I wish I'd written something like this back in September because we went through the exact same thing. That exhausted googling phase is real... I had like 47 tabs open and kept second-guessing whether Moffitt was the right call even though everyone kept saying it was.

The multimodal thing you mentioned really stuck with me because our first consultation somewhere else felt like they were almost surprised we wanted to do chemo AND surgery AND immunotherapy. Like they were doing us a favor instead of it being their standard approach. When we switched to Moffitt it was completely different. They had already mapped out the whole protocol before we even asked. Made a huge difference in how confident we felt.

And yeah the surgeon experience numbers... Joe's was around 180 when we started and I remember thinking okay so this isn't his first rodeo. He could tell us exactly what to expect for the pleural effusion issues and the recovery timeline because he'd seen it so many times. Not just textbook knowledge but actual pattern recognition.

The team thing is exactly what you're describing. I spent three decades in classrooms so I know the difference between people who collaborate and people who just happen to work in the same building. When all three of them sat down together I could just feel it. They cared about getting Joe's case right, not just checking boxes.

We're now about 8 weeks into his immunotherapy after the surgery and having that same team following everything makes me sleep a tiny bit better at night. Well, as much as anyone sleeps during this stuff anyway.
Medical Expert Response
What you described at Moffitt is exactly what the data supports. The Flores et al. outcomes data from Memorial Sloan Kettering has consistently shown that surgical volume matters enormously in pleural mesothelioma, and 200 pleurectomies is genuinely a different category of experience than what most thoracic surgeons accumulate in a career.

The multidisciplinary tumor board piece you mentioned, where they were already talking about Joe's case before you walked in, that's not just good bedside manner. It's actually the structural thing that changes outcomes. I've sat in on boards where the radiation oncologist catches something on a scan that the surgeon read differently, and the plan changes right there. That kind of real-time integration doesn't happen when teams are just trading emails about a patient.

One thing families sometimes don't think to ask about is whether the center is enrolling in any active trials. Even if Joe isn't a candidate right now, being at a site with active trial access means options stay open. The DREAM trial data from 2019 really moved the needle on thinking about immunotherapy sequencing with chemo for stage III, and centers that participated in that kind of research tend to stay closer to where the field actually is.

Your instinct on the follow-up protocol is sound. Scan interpretation consistency matters more than people realize in detecting early recurrence, and having a plan for that before you need it is the right call.

Talk to your oncologist about all of this, especially the trial eligibility question, because what applies to Joe specifically depends on his histology and staging details. But your framework for choosing a center was genuinely good thinking.
3 found this helpful
Medical Expert Response
What you laid out here is genuinely one of the most useful breakdowns I've seen on this forum, and I've been doing oncology social work for 12 years so I've read a lot of these posts.

The volume question is so underrated. There's research showing that surgical outcomes for pleural mesothelioma improve significantly at centers doing more than 15 to 20 cases per year, and most community hospitals aren't anywhere close to that. Joe's surgeon at 200+ is operating in a completely different league in terms of pattern recognition for complications.

The team chemistry observation you made, that's not just intuition. That's you picking up on something clinicians call tumor board integration, where the surgical, oncology, and immunotherapy teams are actively building the protocol together rather than handing off a patient like a relay race. When they're finishing each other's sentences in the room with you, it means they talked before you got there. That matters enormously for multimodal planning.

One thing I'd gently add from working with families in this situation... the psychosocial support piece is worth asking about too. Not just for Joe but for you. I've sat with caregivers who were six months in before anyone thought to ask how they were doing. Moffitt does have social work embedded in their oncology program, so if you haven't connected with someone there yet, that's worth a conversation. And if things get heavy, talking to a counselor outside the medical setting can help in ways that are hard to describe.

You're asking exactly the right questions.
2 found this helpful
Medical Expert Response
One thing nobody's mentioned yet and it keeps coming up in my clinic: ask specifically about their tissue banking protocol.

When Joe's team did his initial biopsy, did they preserve extra tissue? Because some centers bank it for molecular profiling, clinical trial eligibility, and emerging biomarker testing down the road. Others process just enough for diagnosis and that's it. I had a patient last year whose tumor had a BAP1 mutation that would have made him eligible for a trial at NIH, but the original center hadn't banked anything. We were stuck.

So when you're doing that first consult, the question I always suggest people bring up is "what happens to my tissue after pathology." A good mesothelioma center will have an answer ready. A less experienced one will look at you a little sideways.

The multimodal team thing you described is real and it matters enormously. But the tissue question is the one most families never think to ask until it's relevant, and by then you can't go back. Talk to Joe's team about this specifically, because protocols vary even within good institutions.
2 found this helpful
Family
Oh wow, that's such a good point and honestly something I didn't even think to ask about at first. Joe's team did mention they'd preserved samples when we talked about potential trials down the road, but I didn't dig into the specifics of how they store it or what they're actually testing for. I'm gonna reach out to his oncologist this week to get the details on that BAP1 stuff you mentioned because if there's a trial he could qualify for later, I want to know now. Did your patient end up finding another center that had banked his tissue or was it just too late by then?
Veteran
Went through something similar picking my center after my June diagnosis. The volume thing is spot on, M. My surgeon had done over 180 pleurectomies and it showed in how he explained what he'd actually seen go wrong and how he'd handle it. That experience made a real difference in my recovery.
Veteran
Got my diagnosis June 2025 after routine VA screening at Naval Station Norfolk so I didn't have the luxury of shopping around like you did. But I'm gonna say the one thing that saved me was asking hard questions about their complication rates, not just success rates. My surgeon at EVMS told me straight up that his pleurectomy patients had maybe a 12% readmission rate in the first 90 days and he walked me through what those were. Infection, fluid buildup, that kind of thing. Not some glossy brochure number. I had my procedure August 2025 and when I spiked a fever at day 14 I wasn't surprised because he'd already prepped me for it. They caught it early, cleared it up, no big deal. The docs who won't talk about their complications are the ones I wouldn't trust. You want the surgeon who's honest about what can go wrong because that means he knows how to handle it when it does.

Share Your Experience

Sign in or create a free account to share your experience.

Discussions in this community are for informational and emotional support purposes only. They do not constitute legal advice, medical advice, or an attorney-client relationship. Always consult a qualified professional for advice specific to your situation. Community Guidelines

Call Now: (800) 400-1805 Free Case Review • Available 24/7